Caroline Voltz-Girolt: Accelerating the Development of Innovative Therapies for Rare Blood Disorders
Caroline Voltz-Girolt, Senior Scientific Pfficer, Office of Advanced Therapies and Haemato-oncology at European Medicines Agency, shared a post on LinkedIn:
” ‘If you want to go fast, go alone. If you want to go far, go together.’
African proverb
But can we go fast together?
AI and gene editing are rapidly reshaping the future of rare blood disorders, bringing new hope for patients through the promise of a cure.
The question is: how can regulators, clinicians, researchers, patients, industry and other stakeholders work together to make this happen?
The European Medicines Agency (EMA) has opened a public consultation on two new draft guidelines:
Comments are welcome until 31 January 2027.
These draft guidelines build on discussions from the EMA workshop on the challenges in drug development, regulation, and clinical practice in haemoglobinopathies, held in July 2024. The workshop brought together regulators, clinicians, patients, HTA bodies, researchers, and other experts to explore key challenges and opportunities in this rapidly evolving field.
Key topics included:
Unmet medical needs and the current treatment landscape in the EU and the US
- Clinical trial design and the selection of meaningful endpoints
- Innovative therapies, including gene-editing approaches
- Bioethics, health technology assessment, and the role of patient registries
A sincere thank you to all colleagues, experts, working parties and committees who contributed to the development of these draft guidelines: Viktoriia Starokozhko, Karri Penttilä, Johanna Lähteenvuo, Antonella Isgro’, Sylvie Benchetrit, Aysun Cetinyurek Yavuz, Florian Lasch, Angelika Geroldinger, Johannes Walter Beiersdorf, Frederike Lentz, Ole Weis Bjerrum, Flora Musuamba, Caroline Pothet, Benjamin Hofner, Sotiris Michaleas, Caroline Voltz, Daniela Philadelphy, Bruno Sepodes with consultation of the methodology Working Party (MWP), the committee for orphan medicines (COMP), the paediatric committee (PDCO) and the committee for advanced therapies (CAT), the pharmacovigilance committee (PRAC) and endorsed by the committee for human medicinal products (CHMP).
And everyone involved in the workshop: Emer Cooke, Ali Taher, John Porter, Mariane de Montalembert, Raffaella Colombatti, Loris Brunetta, Patricia Oneal, Megha Kaushal, Johanna Lähteenvuo, Radhouane Cherif, Laurence Lwoff, Anja Schiel, María del Mar Mañú Pereira, Antonella Isgro‘
We welcome your comments and perspectives.”
Stay updated with Hemostasis Today.
-
Sep 24, 2026, 16:02Leonardo R: Understanding Peripheral Artery Disease in the Modern Era
-
Sep 24, 2026, 15:49Sthanu Subramanian: When HbA1c Does Not Reflect True Glycemia
-
Sep 24, 2026, 15:00Gambo Ramatu: Anemia as a Preventable Pregnancy Challenge
-
Sep 24, 2026, 14:56Holly John: Sickle Cell Disease Beyond Pain and Clinical Outcomes
-
Sep 24, 2026, 14:45Bruce Holland: Ex Vivo Assessment of ActiGraft Clot Formation Under Anticoagulation
-
Sep 24, 2026, 14:33Mohamed El Belghiti Alaoui: Thrombin as a Therapeutic Target in Coagulation
-
Sep 24, 2026, 14:22Integrating Thrombosis Risk Into Menopause Care – World Thrombosis Day
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress